Inozyme Pharma (NASDAQ:INZY) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $14.00 price target on the stock.

A number of other research firms also recently issued reports on INZY. Bank of America cut their target price on shares of Inozyme Pharma from $16.00 to $14.00 and set a buy rating on the stock in a research report on Tuesday, April 9th. Wedbush restated an outperform rating and issued a $15.00 price objective on shares of Inozyme Pharma in a report on Tuesday, May 7th. Wells Fargo & Company began coverage on shares of Inozyme Pharma in a report on Thursday, May 30th. They set an overweight rating and a $14.00 target price for the company. Finally, Needham & Company LLC reissued a buy rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Wednesday, May 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and an average target price of $16.00.

Inozyme Pharma Stock Performance

Shares of Inozyme Pharma stock opened at $4.42 on Tuesday. The firm has a 50 day simple moving average of $4.60 and a 200 day simple moving average of $5.09. Inozyme Pharma has a fifty-two week low of $2.69 and a fifty-two week high of $7.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 14.05 and a quick ratio of 14.05. The firm has a market cap of $273.42 million, a P/E ratio of -3.23 and a beta of 1.53.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, May 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Sell-side analysts predict that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Institutional Trading of Inozyme Pharma

A number of large investors have recently made changes to their positions in INZY. Kennedy Capital Management LLC grew its stake in Inozyme Pharma by 52.2% in the first quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock valued at $3,352,000 after acquiring an additional 150,120 shares during the period. Affinity Asset Advisors LLC lifted its holdings in shares of Inozyme Pharma by 40.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock valued at $20,242,000 after purchasing an additional 756,717 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Inozyme Pharma by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock valued at $18,530,000 after purchasing an additional 33,998 shares during the period. Eventide Asset Management LLC increased its stake in Inozyme Pharma by 1.8% during the 4th quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock worth $13,546,000 after purchasing an additional 54,837 shares in the last quarter. Finally, Superstring Capital Management LP acquired a new stake in Inozyme Pharma during the 4th quarter worth approximately $528,000. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.